Loading...
MTAA
REC
Market cap11bUSD
Apr 04, Last price  
50.65EUR
1D
-1.36%
1Q
-1.36%
Jan 2017
88.15%
Name

Recordati Industria Chimica e Farmaceutica SpA

Chart & Performance

D1W1MN
P/E
26.72
P/S
5.00
EPS
1.90
Div Yield, %
1.24%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
9.02%
Revenues
2.08b
+12.36%
488,308,000576,080,000576,186,000628,435,000689,634,000747,524,000728,134,000762,036,000828,317,000941,630,000987,356,0001,047,676,0001,153,942,0001,288,123,0001,352,235,0001,481,848,0001,448,867,0001,580,074,0001,853,307,0002,082,331,000
Net income
389m
+24.61%
53,964,00064,543,00074,031,00084,865,000100,429,000110,566,000108,580,000116,446,000118,484,000133,678,000161,187,000198,792,000237,406,000288,762,000312,376,000368,825,000354,984,000385,966,000312,336,000389,214,000
CFO
485m
+5.12%
96,895,00083,061,00096,594,00091,820,000147,616,000155,019,000140,575,000121,460,000112,752,000170,119,000179,155,000247,372,000255,436,000272,711,000371,577,000334,027,000403,575,000491,650,000461,691,000485,319,000
Dividend
May 20, 20240.63 EUR/sh
Earnings
May 07, 2025

Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
IPO date
Jan 01, 1984
Employees
4,300
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,082,331
12.36%
1,853,307
17.29%
Cost of revenue
1,516,564
1,358,997
Unusual Expense (Income)
NOPBT
565,767
494,310
NOPBT Margin
27.17%
26.67%
Operating Taxes
101,822
89,099
Tax Rate
18.00%
18.02%
NOPAT
463,945
405,211
Net income
389,214
24.61%
312,336
-19.08%
Dividends
(245,958)
(230,602)
Dividend yield
2.41%
2.85%
Proceeds from repurchase of equity
7,387
(38,619)
BB yield
-0.07%
0.48%
Debt
Debt current
110,181
374,971
Long-term debt
1,380,853
1,363,120
Deferred revenue
Other long-term liabilities
21,239
19,418
Net debt
1,247,667
1,424,486
Cash flow
Cash from operating activities
485,319
461,691
CAPEX
(29,687)
(96,339)
Cash from investing activities
(379,618)
(767,124)
Cash from financing activities
(168,914)
341,277
FCF
642,409
235,392
Balance
Cash
221,812
284,734
Long term investments
21,555
28,871
Excess cash
139,250
220,940
Stockholders' equity
2,051,806
1,862,576
Invested Capital
3,031,778
3,027,631
ROIC
15.31%
15.61%
ROCE
17.07%
14.47%
EV
Common stock shares outstanding
209,142
209,060
Price
48.83
26.01%
38.75
-31.42%
Market cap
10,212,423
26.06%
8,101,084
-31.42%
EV
11,460,090
9,663,079
EBITDA
708,437
620,066
EV/EBITDA
16.18
15.58
Interest
74,455
32,158
Interest/NOPBT
13.16%
6.51%